Prof. Merav Lidar (Sheba Medical Center, Tel Hashomer, Israel) kindly took the time to discuss the 24-week efficacy and safety results from the KEEPsaKE2 trial (NCT03671148). This phase 3 randomized, double-blind trial investigated the humanized immunoglobulin G1 monoclonal antibody, risankizumab, in adults with psoriatic arthritis (PsA).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients’ (ABSTRACT NUMBER: 0183) was presented at the ACR Convergence, 5-9 November 2021.
Questions
- Could you tell us a little about risankizumab and its mechanism of action? (0:11)
- What were the aims, design and inclusion criteria of the KEEPsAKE 2 clinical trial? (1:06)
- What were the safety findings from the study? (2:07)
- Could you tell us a little about the efficacy findings from the trial? (3:02)
- How will risankizumab impact clinical practice if approved? (4:36)
Disclosures: Prof. Merav Lidar has participated in an advisory board for AbbVie.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
